NCT05042375 2022-11-17A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd.Phase 3 Unknown450 enrolled